331467-03-9
331467-03-9
Chemical Structure
5-Iodo-indirubin-3'-monoxime
- CAS No.: 331467-03-9
- Formula:C16H10IN3O2
- Molecular Weight:403.17
IUPAC Name: (2Z,3E)-3-(hydroxyimino)-5'-iodo-[2,3'-biindolinylidene]-2'-one
InChIKey: PDPYYDKCSZQJMS-WAVHTBQISA-N
SMILES: O/N=C(C1=CC=CC=C1N2)/C2=C3C(NC4=C/3C=C(I)C=C4)=O
Biological Activity: 5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC50s of 9, 20 and 25 nM, respectively[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
5-Iodo-indirubin-3'-monoxime | 98.12% | 5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC50s of 9, 20 and 25 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Iodo-indirubin-3'-monoxime (Standard) | ≥98% | 5-Iodo-indirubin-3'-monoxime (Standard) is the analytical standard of 5-Iodo-indirubin-3'-monoxime (HY-111930). This product is intended for research and analytical applications. 5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the Kinase, with IC50s of 9, 20 and 25 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.85
HY-1034645'-Fluoroindirubinoxime -
Similarity Score 0.82
HY-139254Indirubin-3′-oxime -
Similarity Score 0.82
HY-19807Indirubin-3'-monoxime -
Similarity Score 0.81
HY-131448A3334 -
Similarity Score 0.81
HY-178227KY19334 -
Similarity Score 0.81
HY-10580GSK 3 Inhibitor IX -
Similarity Score 0.77
HY-111931Indirubin-3'-monoxime-5-sulphonic acid -
Similarity Score 0.76
HY-1210357BIO -
Similarity Score 0.75
HY-156879Antiproliferative agent-40 -
Explore the MedChemAI to find more analogs
